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Lung cancer is an important etiology of malignant mortality worldwide with global statistics indicating over 1
million deaths annually. Although there have been advances in cytotoxic chemotherapy, the prognosis after
treatment still remains poor. Remarkably, recent studies on the molecular level are creating the possibility to
hamper lung cancer by inhibiting the hedgehog pathway. Currently, hedgehog pathway inhibitors include IWP-2,
cyclopamine and aprotinin. However, Vismodegib is a new upcoming prospect which has shown positive results
while undergoing clinical trials. If approved, it may lead to a novel class of anti-cancer therapy for patients seeking
treatment for small cell lung cancer.
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Lung cancer is an important etiology of malignant mor-
tality worldwide with global statistics indicating over 1
million deaths each year [1]. Despite advances in cyto-
toxic chemotherapy in addition to traditional treat-
ments, the prognosis still remains poor due to limited
efficacy. Remarkably, recent studies on the molecular
level have created the possibility to detect, prevent and
treat small cell lung cancer in its initial stage by
inhibiting a novel pathway involved in embryogenesis
known as the Hedgehog (Hh) pathway.
The Hh pathway involves a family of secreted proteins
that participate in the regulation of cell growth, diffe-
rentiation and survival [2,3]. Furthermore, these unique
proteins have also been implicated in promoting stem
cell proliferation in adults. However, if they are abnor-
mally hyperactivated in adult tissues through sporadic
mutations or other mechanisms, they may play a crucial
role in tumorigenesis of various organs especially the
lungs [4-6]. Amongst these, the ones recently discovered
to contribute in small cell lung cancer [7,8] develop-
ment are Smoothened (SMO), Rab23, platelet-derived
growth factor alpha (PDGFRα), hedgehog interacting* Correspondence: sh.abbas.naqvi@gmail.com
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reproduction in any medium, provided the orprotein (HIP) and hepatocyte nuclear factor 3-beta
(HNF3β) [5]. For this reason, the use of Hh pathway
inhibitors in lung cancer have strongly been considered.
Hh pathway inhibitors are a novel class of therapeutic
agents that specifically target proteins which are involved
in the regulation of the Hh pathway. Currently, the inhibi-
tors include IWP-2, cyclopamine and aprotinin; each
one altering one of the mutated afore mentioned proteins
to prevent malignancy by inhibiting wnt/β-catenin
pathway [9], blocking hedgehog signaling by binding to
heptahelical bundle of smoothened (smo) [10] and as pro-
tease inhibitor [11], respectively. In addition, itraconazole
(Sporanox) are a different class of drugs which have also
shown potential; having the same action as cyclopamine
except through a different mechanism [12] while arsenic
trioxide antagonizes the Hedgehog pathway by preventing
ciliary accumulation thus reducing stability of the Gli2
transcriptional effector [13]. Although these drugs have
been successful in treating invasive cancers, their role in
lung cancer therapy remains to be determined. Many
studies have discussed the potential role of HHIs in small
cell lung cancer but a lot of these drugs are still in their
trial phase. Various studies discussed new strategies of
lung cancer management with a possible role of HHI in
future [14,15].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Naqvi et al. Infectious Agents and Cancer 2013, 8:17 Page 2 of 2
http://www.infectagentscancer.com/content/8/1/17Interestingly, Vismodegib (trade name Erivedge) is a
new upcoming prospect which has shown positive re-
sults for inhibiting the Hh pathway in different cancer
while undergoing clinical trials in the United States
[16]. It acts to suppress Hh signaling by binding to and
interfering with smoothened, a membrane protein that
provides positive signals to the Hh signaling pathway
[17]. Moreover, this drug is extensively bound to plasma
proteins which accounts for its longer half-life [18]. Its
recent approval for the treatment of advanced basal cell
carcinoma (BCC) has now made it a viable candidate
in lung cancer therapy. However, like other drugs
Vismodegib also has side effects including muscle
spasms, weight loss, dysguesia, alopecia and constipa-
tion [19]. Nevertheless, if Vismodegib is approved by
the Food and Drug Administration (FDA) for small cell
lung cancer, it may lead to a novel class of anti-cancer
therapy for patients seeking treatment for lung cancer.
Moreover, these advancements may potentially lead to a
cascade of new clinical trials with more Hh inhibiting
drugs being tested for their safety and efficacy. Optimis-
tically, these alone, or in combination with traditional
therapy, may provide the breakthrough oncologists need
in their struggle to find a definite cure. However, for this
notion to be successful, collaborative multiinstitutional
efforts will be necessary.
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